Alternate-Day Buprenorphine Administration. Phase II - 4
Summary
The purpose of this study is to determine if two times a subject's daily maintenance dose will hold for 48 hours without changes in agonist and antagonist effects.
Study Design
Control: Placebo Control, Intervention Model: Crossover Assignment, Primary Purpose: Treatment
Conditions
Opioid-Related Disorders
Intervention
Buprenorphine
Location
Treatment Research Center
Burlington
Vermont
United States
05401
Status
Completed
Source
National Institute on Drug Abuse (NIDA)
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00000222
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-07-24T14:36:47-0400
Clinical Trials
Buprenorphine Maintenance for Opioid Addicts - 2
The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The...
Buprenorphine Dose Alteration Study - 1
The purpose of this study is to examine the effects in buprenorphine dose alterations in opioid dependent individuals being maintained on buprenorphine.
Buprenorphine Maintenance for Opioid Addicts - 1
The purpose of this study is to evaluate the efficacy of buprenorphine and desipramine in treatment of opiate and cocaine dependence.
Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users
Buprenorphine is a medication used to treat opioid addiction, but individuals who use this drug are at risk of abusing it. A buprenorphine and naloxone combination may reduce the likelihoo...
PubMed Articles
Opioid use disorders are a major medical and public health concern. Buprenorphine is approved for the treatment of opioid use disorders; however, a shortage of physicians prescribing buprenorphine is ...
Rates of non-medical use of opioids, and opioid use disorders (OUD) have been rising throughout North America. Methadone and buprenorphine/naloxone are the recommended first-line treatment options for...
Use of various psychoactive substances can influence outcomes of patients on opioid agonist treatment (OAT). While use of alcohol and cocaine has shown to adversely affect OAT results, associated cann...
Prescribing patterns of buprenorphine waivered physicians.
DATA 2000 enabled physicians with approved training to be waivered to prescribe buprenorphine for the treatment of opioid use disorders (OUD) for a limited number of patients. A rule change in 2016 in...
Extended-release naltrexone (XR-NTX), an opioid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmacologically and conceptually distinct interventions to p...
Medical and Biotech [MESH] Definitions
Buprenorphine
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
Buprenorphine, Naloxone Drug Combination
A pharmaceutical preparation that combines buprenorphine, an OPIOID ANALGESIC with naloxone, a NARCOTIC ANTAGONIST to reduce the potential for NARCOTIC DEPENDENCE in the treatment of pain. It may also be used for OPIATE SUBSTITUTION THERAPY.
Opioid-related Disorders
Disorders related or resulting from abuse or mis-use of opioids.
Opiate Substitution Treatment
Medical treatment for opioid dependence using a substitute opiate such as METHADONE or BUPRENORPHINE.
Bipolar And Related Disorders
These disorders are related to both SCHIZOPHRENIA SPECTRUM AND RELATED DISORDERS and DEPRESSIVE DISORDERS in terms of symptomatology, family history, and genetics. (DSM-V) .
